Refine by
Myocardial Ischemia Articles & Analysis
9 news found
Elucid has developed FDA-cleared Plaque Analysis and investigational FFRCT tools designed to enable physicians to diagnose and understand the direct cause of myocardial ischemia, while also identifying coronary plaque that is at highest risk to rupture and result in a heart attack. ...
ByElucid
” "In addition to our critically important autologous cell therapies being studied for ischemic heart failure and chronic myocardial ischemia with refractory angina, the FDA's acceptance of this IND for patients recovering from ARDS is an important milestone in the development of our allogeneic mesenchymal stem cell therapy platform and validation for its ...
The code provides clear reimbursement for the study procedure performed for both the treatment and control arms for the ongoing cell therapy pivotal trials in two cardiovascular indications: the CardiAMP Cell Therapy Heart Failure Trial (NCT02438306) and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial (NCT03455725). “This most recent action by ...
BioCardia also partners with other biotherapeutic companies to provide its Helix systems and development support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. The CardiAMP Cell Therapy Heart Failure Trial has been supported financially by the Maryland Stem ...
There is now an abundance of published literature on atherosclerosis which has long defined lipid-rich necrotic core as the major culprit for cardiovascular disease progression that leads to myocardial ischemia and acute events. “Obtaining reimbursement for providers to identify key biomarkers of arterial narrowing and plaque stability will advance the ...
ByElucid
[Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ...
CardiAMP Autologous Cell Therapy for Chronic Myocardial Ischemia (BCDA-02) The pivotal CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial has been activated and the first patient was consented during the quarter. ...
This latest round of financing will enable us to continue advancing our unique technology for non-invasive estimation of cardiovascular event risk, myocardial ischemia, and therapeutic response. This funding is validation of the market need for technology like Elucid’s to enable more accurate diagnosis of cardiovascular disease and patient-specific ...
ByElucid
The expert report highlights health effects, with different levels of scientific evidence: effects such as sleepiness, reduced sleep quality and reduced total sleeping time, and metabolic syndrome are proven; the effects on mental health, cognitive performance, obesity and weight gain, type 2 diabetes and coronary heart disease (coronary ischemia and ...